Gene Signal is looking to develop strategic partnerships with key industry-leading companies to facilitate the development and marketing of its current discovery stage and clinical stage drug portfolio, as well as partners to facilitate entry into the Americas.    

We are  seeking to enter licensing agreements with key partners to either commercialize or co-develop our therapeutic portfolio.

• In Ophthalmology key indications include Corneal Graft Rejection (eyedrops, Phase III ), Neovascular Glaucoma (ointment, Phase I), Retinopathy of Prematurity (ointment or intravitreal, Phase I), as well as Age Related Macular Degeneration (ointment or intravitreal, pre-clinical) and Diabetic Retinopathy (ointment or intravitreal, pre-clinical) .
• In Dermatology & Vascular key indications include Psoriasis and Rosacea (ointment, Phase I) and Wound Healing (ointment or intravitreal, Pre-Clinical). 
• In Oncology, key indications include Kidney Cancer, Lung Cancer and Pancreatic Cancer (Proof of Concept). 

The desired partner is to contribute to Gene Signal’s scientific expertise and most importantly partner with Gene Signal in the development and running of clinical trails and later assume responsibility for product commercialization.

For more information please contact: ev@genesignal.com